HEINRICH TAEGTMEYER, M.D.

HOUSTON, TX

Research Active
Internal Medicine - Cardiovascular Disease NPI registered 20+ years 50 publications 2018 – 2025 NPI: 1851325856

Practice Location

6410 FANNIN ST
HOUSTON, TX 77030-3000

Phone: (832) 325-7211

What does HEINRICH TAEGTMEYER research?

Heinrich Taegtmeyer's research explores how metabolic functions influence heart health, particularly in conditions like heart failure, atrial fibrillation, and genetic disorders affecting blood flow. He looks at how energy production within heart cells can lead to better treatment methods, such as optimizing the timing of medications or identifying new therapies to enhance heart function. Additionally, he studies the impacts of substance use, like alcohol, on the heart and investigates metabolic disorders linked to chronic diseases, aiming to uncover ways to prevent and treat complications for patients suffering from these conditions.

Key findings

  • Boosting energy production in immature smooth muscle cells in genetic models led to significantly fewer strokes and reduced artery blockages in treated mice compared to untreated groups.
  • Long-term GLP1 therapy reduced post-meal inflammation (specifically IL6 levels) in obese individuals with prediabetes, indicating a potential for improved management of metabolic health.
  • Increased activity of the protein NR4A2 in heart cells caused severe heart problems, such as heart enlargement and failure, within approximately 40 days in mice, underscoring its role in heart disease.
  • Alcohol consumption was found to increase the risk of atrial fibrillation, emphasizing its status as a controllable risk factor for heart conditions.
  • In chronic kidney disease patients, higher levels of the SIRPα protein correlated with worsened heart function and increased heart muscle damage, suggesting potential therapeutic targets.

Frequently asked questions

Does Dr. Taegtmeyer study heart conditions?
Yes, he focuses on various heart conditions, including heart failure and atrial fibrillation.
What treatments has Dr. Taegtmeyer researched?
He has researched treatments involving metabolic enhancement in heart cells and the impact of diabetes medications on heart health.
Is Dr. Taegtmeyer's work relevant to diabetes?
Absolutely, he studies how metabolic processes related to diabetes can affect heart health and explores potential treatments for prediabetes and obesity.
How can his research help children with moyamoya disease?
His findings on boosting energy production in affected cells may provide new treatment options to prevent strokes in children with this condition.
What is the link between alcohol and heart health in his studies?
Dr. Taegtmeyer found that even moderate drinking can increase the risk of heart problems, particularly atrial fibrillation.

Publications in plain English

Immature Acta2smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOS.

2025

Nature communications

Kaw A, Majumder S, Esparza Pinelo JE, Wu T, Starosolski Z +18 more

Plain English
This study looked at how specific changes in a gene called ACTA2 lead to a disease that causes strokes in children, similar to moyamoya disease. Researchers found that muscle cells related to blood vessels in mice with these genetic changes remained immature and overly mobile, leading to dangerous blockages in blood flow. By boosting a specific type of cellular energy production, they could promote proper cell growth and prevent these issues, resulting in a significant reduction in stroke symptoms in treated mice. Who this helps: This helps children with ACTA2-related moyamoya disease and their doctors by identifying potential treatments.

PubMed

A brief history of circadian time in the heart.

2025

Journal of molecular and cellular cardiology

Young ME, Khanna V, Metcalfe M, Rameshkumar N, Harington S +4 more

Plain English
This paper reviews how our understanding of the body's internal clock, or circadian rhythms, affects heart health. Researchers found that the time of day significantly influences heart functions, including changes in heart rate and blood pressure. These insights could lead to better treatments, like timing surgeries and medications to match the body’s natural rhythms, ultimately improving heart health and extending life. Who this helps: Patients with heart conditions and healthcare providers.

PubMed

Chronic GLP1 therapy reduces postprandial IL6 in obese humans with prediabetes.

2024

Cardiovascular endocrinology & metabolism

Hamidi V, Wang H, Pham V, Bermudez Saint Andre K, Taegtmeyer H +1 more

Plain English
This study looked at how long-term treatment with a medication called GLP1 affects inflammation in people who are obese and prediabetic. After six weeks of treatment, blood tests showed that a substance called IL6, which is linked to inflammation, decreased after meals, indicating less inflammation in the body. This is important because it suggests that chronic GLP1 therapy might help manage inflammation in these patients, which can reduce their risk of developing diabetes. Who this helps: This benefits patients with obesity and prediabetes, particularly those looking to reduce inflammation and improve their health.

PubMed

Autophagic signaling promotes systems-wide remodeling in skeletal muscle upon oncometabolic stress by D2-HG.

2024

Molecular metabolism

Gao Y, Kim K, Vitrac H, Salazar RL, Gould BD +17 more

Plain English
This study looked at how a compound produced in certain cancers, called D2-hydroxyglutarate (D2-HG), affects skeletal muscle and contributes to muscle loss, which is a significant issue in conditions like cancer and heart failure. The researchers found that D2-HG disrupts normal cell functions leading to muscle weakening and atrophy; specifically, male mice showed greater muscle loss and reduced grip strength compared to female mice. This research is important because it identifies new metabolic weaknesses that could be targeted for therapies to help prevent muscle loss in patients with these conditions. Who this helps: This helps patients suffering from cancer-related muscle loss and their doctors.

PubMed

ATP-dependent citrate lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling of the Heart.

2024

bioRxiv : the preprint server for biology

Liu S, Gammon ST, Tan L, Gao Y, Kim K +23 more

Plain English
This study looked at how a protein called ATP-dependent citrate lyase (ACL) affects heart function, particularly in patients with a condition called hypertrophic cardiomyopathy. The researchers found that when ACL is removed, the heart compensates by increasing sugar metabolism, but this also highlights weaknesses in the heart's overall metabolism. Knowing how ACL influences heart function is important because it could help identify new treatments for heart problems. Who this helps: This helps patients with heart diseases and their doctors by providing insights into potential new therapies.

PubMed

Alcohol and Atrial Fibrillation: An Update and New Perspectives.

2024

The American journal of medicine

Hatley M, Lam T, Ekeruo I, Taegtmeyer H

Plain English
This study looked at how drinking alcohol affects the heart, particularly a condition called atrial fibrillation, which is an irregular heartbeat. Researchers found that drinking alcohol, even in moderate amounts, can lead to heart problems, including atrial fibrillation triggered by binge drinking. They concluded that alcohol should be seen as a controllable risk factor for this heart condition and other heart diseases, emphasizing that many people might not realize the full impact of their drinking habits. Who this helps: This helps patients who drink alcohol and may be at risk for heart problems.

PubMed

Metabolic cycles: A unifying concept for energy transfer in the heart.

2024

Journal of molecular and cellular cardiology

Beito M, Taegtmeyer H

Plain English
This study looked at how the heart uses energy and how changes in this process can cause problems in heart function, particularly in heart disease. Researchers found that in failing hearts, levels of a molecule called pyruvate were high, but other important substances for energy production were low. They suggest that increasing the expression of a specific protein that helps transport pyruvate can improve heart function by restoring energy production cycles, which could be a new way to support heart health. Who this helps: This research benefits patients with heart failure and their doctors.

PubMed

Hermann ("Hugh") Blaschko (1900-1993): Father of Catecholamine Metabolism.

2023

Cardiology

Taegtmeyer H, Ganim J, Leuppi-Taegtmeyer AB

PubMed

The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure.

2023

JACC. Heart failure

Rodolico D, Schiattarella GG, Taegtmeyer H

Plain English
This research paper explored how the heart's energy use affects its ability to function properly, especially in cases of heart failure. The study highlights that heart failure may be due to problems with how the heart transfers energy, which can lead to both structural and functional issues. New imaging techniques could help better understand these changes and lead to more effective treatments. Who this helps: This information benefits patients with heart failure and their doctors by improving diagnosis and treatment options.

PubMed

Fetal metabolic adaptations to cardiovascular stress in twin-twin transfusion syndrome.

2023

iScience

Parchem JG, Fan H, Mann LK, Chen Q, Won JH +4 more

Plain English
This study looked at how fetuses adapt their metabolism when faced with cardiovascular stress caused by twin-twin transfusion syndrome (TTTS), a condition in shared placenta twin pregnancies where one twin receives more blood than the other. They found that in severe cases of TTTS, changes occurred in the metabolism of fatty acids, glucose, and hormones, indicating that the fetal heart can adjust its glucose use in response to stress. Notably, there were distinct differences in metabolite levels between the twins, suggesting that their ability to cope with this stress varies. Who this helps: This information can help doctors better understand and manage complications in twins affected by TTTS.

PubMed

More on the Magic of Metformin.

2023

Cardiology

Koutroumpakis E, Huang-Lucas C, Taegtmeyer H

PubMed

A Complement to the H-Index: A Metric Based on Primary Authorship.

2023

The American journal of medicine

Dasgupta P, Taegtmeyer H

PubMed

A Two-Step Transcriptome Analysis of the Human Heart Reveals Broad and Disease-Responsive Expression of Ectopic Olfactory Receptors.

2023

International journal of molecular sciences

Ashraf S, Frazier OH, Carranza S, McPherson DD, Taegtmeyer H +1 more

Plain English
This study looked at special receptors called ectopic olfactory receptors (ORs) in the human heart to understand their role in heart failure, specifically in patients with heart damage from blood flow issues. Researchers analyzed heart tissue from 18 patients with heart failure and 4 healthy individuals, finding over 160 different ORs present in the heart, with 38 of these receptors changing when heart failure occurred. These findings are important because they suggest that the altered functioning of these receptors could help explain heart failure’s effects on energy use and inflammation, potentially leading to new treatments. Who this helps: This helps patients with heart failure and doctors looking for better treatment options.

PubMed

Augmenting Mitochondrial Respiration in Immature Smooth Muscle Cells with anPathogenic Variant Mitigates Moyamoya-like Cerebrovascular Disease.

2023

Research square

Kaw A, Wu T, Starosolski Z, Zhou Z, Pedroza AJ +15 more

Plain English
This study looked at how a specific genetic change affects the development of moyamoya-like cerebrovascular disease, which causes strokes in children. Researchers found that treating immature smooth muscle cells in mice with a substance called nicotinamide riboside (NR) led to better cell development and reduced the occurrence of strokes. Specifically, in mice treated with NR, there were fewer strokes and significantly less blockage in the arteries compared to untreated mice. Who this helps: This benefits children at risk of moyamoya disease and their doctors by providing a potential treatment option to prevent strokes.

PubMed

Strategies for Imaging Metabolic Remodeling of the Heart in Obesity and Heart Failure.

2022

Current cardiology reports

Haidar A, Taegtmeyer H

Plain English
This research studied how obesity and heart failure change the way the heart processes energy, and it explored noninvasive imaging methods to see these changes. The study found that specific imaging tools, including glucose and fatty acid tracers like F-FDG, can help assess heart metabolism. These findings are important because understanding these changes can help doctors better diagnose and treat heart issues linked to obesity. Who this helps: This benefits patients with obesity and heart failure, as well as their doctors.

PubMed

Letter by Lucas and Taegtmeyer Regarding Article, "One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction".

2022

Circulation

Huang Lucas C, Taegtmeyer H

PubMed

2022 Beijing Winter Olympics: Spotlight on Cardiac Metabolism.

2022

Circulation

Taegtmeyer H, Zaha VG, McGuire DK

PubMed

SIRPα Mediates IGF1 Receptor in Cardiomyopathy Induced by Chronic Kidney Disease.

2022

Circulation research

Thomas SS, Wu J, Davogustto G, Holliday MW, Eckel-Mahan K +5 more

Plain English
This study examined how a protein called SIRPα affects heart problems caused by chronic kidney disease (CKD). Researchers found that higher levels of SIRPα in both mice and human patients with CKD led to worse heart function and increased heart muscle damage. Specifically, when SIRPα was removed from the heart muscle of mice, their heart function improved significantly compared to mice with CKD that still had SIRPα. Who this helps: This research benefits patients with chronic kidney disease by providing insights into potential heart disease treatments.

PubMed

Prolonged cardiac NR4A2 activation causes dilated cardiomyopathy in mice.

2022

Basic research in cardiology

Ashraf S, Taegtmeyer H, Harmancey R

Plain English
This study looked at how increasing the activity of a specific protein called NR4A2 in heart cells affected mice. Researchers found that when NR4A2 was overactive, the mice developed serious heart problems, including heart enlargement and heart failure, within about 40 days. This is important because it highlights how NR4A2 affects heart cell behavior and may provide insights into new ways to treat heart diseases. Who this helps: This research could benefit doctors and patients dealing with heart conditions.

PubMed

Cardio-Onco-Metabolism - Metabolic vulnerabilities in cancer and the heart.

2022

Journal of molecular and cellular cardiology

Karlstaedt A, Taegtmeyer H

Plain English
This research paper focuses on how cancer and heart diseases are connected through changes in metabolism. The authors found that both tumors and failing hearts alter their metabolism to get the energy they need, which can lead to heart problems in cancer survivors. This is important because it can help create new tests and treatments for patients at risk of heart disease after cancer. Who this helps: Patients who have survived cancer.

PubMed

Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes.

2022

Cell reports. Medicine

Gutierrez AD, Gao Z, Hamidi V, Zhu L, Saint Andre KB +8 more

Plain English
This study looked at how a diabetes medication, called GLP1 analogs, helps manage blood sugar by exploring a protein called interleukin-6 (IL-6). They found that when people with prediabetes took liraglutide, it increased IL-6 levels in their bodies and led to better fat metabolism and weight loss. Specifically, they observed that blocking IL-6 reduced the drug's effectiveness in helping the body burn fat and manage glucose. Who this helps: This benefits patients with prediabetes and type 2 diabetes looking for effective treatments.

PubMed

Diverging consequences of hexosamine biosynthesis in cardiovascular disease.

2021

Journal of molecular and cellular cardiology

Li Q, Taegtmeyer H, Wang ZV

PubMed

Heart Failure in Diabetes: Still a Vexing Problem.

2021

Circulation research

Taegtmeyer H

PubMed

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).

2021

Autophagy

Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A +2924 more

Plain English
This study created updated guidelines for scientists on how to measure and understand autophagy, a process where cells break down and recycle their own components. The researchers highlighted that there are many ways to study autophagy, and no single method is perfect for every situation; instead, combining different techniques provides better insights. They emphasized that understanding these methods is crucial as they can impact how treatments are developed for diseases related to cell functioning. Who this helps: This helps researchers and scientists studying diseases linked to cell health and function.

PubMed

Geographical Differences in Cardiovascular Comorbidities and Outcomes of COVID-19 Hospitalized Patients in the USA.

2021

Cardiology

Koutroumpakis E, Hashmi SS, Powell C, Fatakdawala M, Pang J +17 more

Plain English
This study compared hospitalized COVID-19 patients in Texas and New York to see how different heart-related health issues affected their outcomes. It found that Texas patients were generally younger and had more diabetes, while New York patients had more heart disease. However, Texas patients required more intensive treatments like mechanical ventilation and stayed in the hospital longer, even though overall death rates were similar for both groups. Who this helps: This helps doctors and healthcare providers understand regional differences in patient needs during COVID-19.

PubMed

Obesity and Heart Failure with Preserved Ejection Fraction.

2021

Heart failure clinics

Koutroumpakis E, Kaur R, Taegtmeyer H, Deswal A

Plain English
This study focused on a specific type of heart failure known as HFpEF, particularly in obese patients. Researchers found that obesity significantly affects heart function through various mechanisms, and that losing weight can lead to better health outcomes. It also highlighted new treatment options that can help manage heart issues related to obesity, such as specific medications that improve heart function and reduce fat around organs. Who this helps: Patients with obesity-related heart failure.

PubMed

Metabolic remodeling precedes mTORC1-mediated cardiac hypertrophy.

2021

Journal of molecular and cellular cardiology

Davogustto GE, Salazar RL, Vasquez HG, Karlstaedt A, Dillon WP +9 more

Plain English
In this study, researchers looked at how a protein complex called mTORC1 affects heart growth, specifically examining how changes in heart metabolism happen before actual growth occurs. They found that before the heart muscle thickens (a condition called hypertrophy), glucose usage decreases while certain glucose levels increase. This process leads to heart growth without progressing to heart failure, and the researchers also noted that a drug called rapamycin can stop these changes. Who this helps: This research benefits doctors and patients at risk for heart conditions by providing insights into heart growth processes.

PubMed

Icons in Cardiology.

2021

Cardiology

Taegtmeyer H, Atar D

PubMed

Richard J. Bing, MD (1909-2010).

2021

Cardiology

Taegtmeyer H

PubMed

Homeostasis Disrupted and Restored-A Fresh Look at the Mechanism and Treatment of Obesity During COVID-19.

2021

Frontiers in cardiovascular medicine

Dickey J, Davtyan C, Davtyan D, Taegtmeyer H

Plain English
This study looked at how obesity affects health, especially during the COVID-19 pandemic, and explored ways to treat it, such as diet changes and bariatric surgery. It found that intermittent fasting can improve insulin sensitivity, while dieting can significantly reduce harmful belly fat. Bariatric surgery can quickly help with type 2 diabetes before major weight loss occurs. Understanding the best treatment is important for helping obese individuals improve their health. Who this helps: This helps patients with obesity and their healthcare providers.

PubMed

Strategies of Unloading the Failing Heart from Metabolic Stress.

2020

The American journal of medicine

Koutroumpakis E, Jozwik B, Aguilar D, Taegtmeyer H

Plain English
This study looked at how heart failure in patients with type 2 diabetes happens when the heart has too much fuel, which disrupts its normal function. The researchers found that limiting fuel intake through strategies like dieting or surgery can actually help the heart work better, in contrast to treatments that increase fuel supply, which can worsen heart function. This matters because improving the heart's metabolism can lead to better health outcomes for patients struggling with both heart failure and diabetes. Who this helps: This helps patients with heart failure and type 2 diabetes.

PubMed

Re-balancing cellular energy substrate metabolism to mend the failing heart.

2020

Biochimica et biophysica acta. Molecular basis of disease

Glatz JFC, Nabben M, Young ME, Schulze PC, Taegtmeyer H +1 more

Plain English
This study examined how the heart uses energy from fats and sugars during stress and found that an imbalance, where the heart relies too much on either fats or sugars, can lead to heart problems. Researchers believe that adjusting the heart's energy sources back to a balanced mix of fats and sugars can improve heart function. This is important because finding ways to help the heart work better can be crucial for treating heart disease. Who this helps: This helps patients with heart failure.

PubMed

Glucose 6-Phosphate Accumulates via Phosphoglucose Isomerase Inhibition in Heart Muscle.

2020

Circulation research

Karlstaedt A, Khanna R, Thangam M, Taegtmeyer H

Plain English
Researchers studied how a specific enzyme called phosphoglucose isomerase (PGI) affects the metabolism of heart muscle cells in the context of heart failure. They found that when PGI activity is reduced, a substance called glucose 6-phosphate (G6P) builds up, which leads to increased activation of a key growth pathway in the heart known as mTOR; this was confirmed through various experiments where changes in G6P levels directly influenced protein production in heart cells. Understanding this process is important because it reveals potential targets for treatments that could help improve heart function in patients with heart failure. Who this helps: Patients with heart failure.

PubMed

Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries.

2020

Kidney international

Verma N, Liu M, Ly H, Loria A, Campbell KS +9 more

Plain English
This study looked at how a hormone called amylin, which is linked to type-2 diabetes, affects red blood cells and blood vessels before diabetes fully develops. Researchers found that high levels of amylin change the shape and reduce the function of red blood cells, leading to serious problems like increased risk of heart failure, cancer, and stroke. Specifically, they discovered that amylin-coated red blood cells were associated with lower levels of healthy hemoglobin and issues in small blood vessels, showing that targeting amylin could help prevent diabetic complications. Who this helps: This research benefits patients with type-2 diabetes by identifying potential new ways to reduce complications.

PubMed

Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.

2020

Metabolic syndrome and related disorders

Hamidi V, Riggs K, Zhu L, Bermudez Saint Andre K, Westby C +6 more

Plain English
This study looked at how a drug called exenatide affects blood vessel behavior in people with prediabetes after eating a high-fat meal. It involved 15 obese adults and found that exenatide reduced blood flow in the forearms after meals—showing a decrease three hours after eating (with a significance level of 0.003) and a nearly significant decrease six hours post-meal (0.056). This is important because it suggests that exenatide might influence blood flow and metabolism differently than other treatments, potentially impacting how these patients manage their condition. Who this helps: This helps patients with prediabetes.

PubMed

Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats.

2020

Journal of the American Heart Association

Li J, Minćzuk K, Massey JC, Howell NL, Roy RJ +8 more

Plain English
This study looked at how metformin, a common diabetes medication, affects heart health in a type of rat that naturally develops high blood pressure. Researchers found that metformin lowered blood pressure and improved heart function: it helped normalize heart glucose use, decreased heart size and thickness, and improved the heart's ability to pump blood. These findings are important because they suggest that metformin could help prevent heart problems associated with high blood pressure. Who this helps: Patients with high blood pressure or related heart conditions.

PubMed

Intracellular sodium elevation reprograms cardiac metabolism.

2020

Nature communications

Aksentijević D, Karlstaedt A, Basalay MV, O'Brien BA, Sanchez-Tatay D +7 more

Plain English
This study looked at how high levels of sodium inside heart cells affect heart metabolism during both acute and chronic conditions. Researchers found that increased sodium leads to notable changes in how the heart uses energy, shifting from burning fat to using carbohydrates, which is not ideal for heart function. They also discovered that by blocking a specific sodium-calcium exchanger, they could reduce these unhealthy metabolic changes, suggesting a potential new treatment strategy for heart failure. Who this helps: This benefits patients with heart failure and their doctors.

PubMed

Transient activation of AMPK preceding left ventricular pressure overload reduces adverse remodeling and preserves left ventricular function.

2019

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Nam DH, Kim E, Benham A, Park HK, Soibam B +6 more

Plain English
This study looked at how temporarily activating a protein called AMPK can help protect the heart from damage when it's under pressure due to conditions like high blood pressure. In mice that lacked a protein called SRC-2, activating AMPK before a pressure overload significantly improved heart function and reduced harmful changes in the heart's structure, showing a marked decrease in scarring. Specifically, AMPK activation led to better heart performance in these mice compared to those that did not receive this treatment. Who this helps: This research benefits patients with heart conditions and their doctors by providing insights into potential new treatments.

PubMed

Metabolic Changes in Spontaneously Hypertensive Rat Hearts Precede Cardiac Dysfunction and Left Ventricular Hypertrophy.

2019

Journal of the American Heart Association

Li J, Kemp BA, Howell NL, Massey J, Mińczuk K +11 more

Plain English
This study looked at how the hearts of rats with high blood pressure change before they show signs of serious heart problems. Researchers found that these rats showed increased glucose uptake and reduced heart function as early as two months old, even before their hearts became noticeably thicker or larger. This is important because identifying these early metabolic changes can help doctors detect heart issues caused by high blood pressure sooner, allowing for earlier treatment. Who this helps: Patients with high blood pressure and their doctors.

PubMed

Non-cytotoxic Cardiac Innate Lymphoid Cells Are a Resident and Quiescent Type 2-Commited Population.

2019

Frontiers in immunology

Bracamonte-Baran W, Chen G, Hou X, Talor MV, Choi HS +6 more

Plain English
This study looked at a specific type of immune cells in the heart called non-cytotoxic innate lymphoid cells (ILCs). The researchers found that in healthy hearts, these cells mostly stay quiet but have the potential to respond during inflammation, such as in heart conditions like myocarditis, where they can turn into more active cells. They discovered that in damaged hearts, especially with conditions like heart attacks, these cells grow and become more inflammatory, showing a direct link between heart tissue damage and immune response. Who this helps: This research benefits doctors and patients with heart disease by improving understanding of the immune response in heart conditions.

PubMed

The Cardiac Microenvironment Instructs Divergent Monocyte Fates and Functions in Myocarditis.

2019

Cell reports

Hou X, Chen G, Bracamonte-Baran W, Choi HS, Diny NL +12 more

Plain English
This study examined how two types of immune cells (monocytes) behave in a condition called myocarditis, which is inflammation of the heart. Researchers found that a protein called IL-17A affects these cells by slowing their ability to mature into macrophages, which are important for cleaning up dead cells in the heart. In patients with heart failure, higher levels of IL-17A were linked to lower effectiveness in cleaning up these dead cells, which can worsen heart damage. Who this helps: This helps patients with heart conditions, especially those with myocarditis and heart failure.

PubMed

andin Lockstep: Thoughts on the Enduring Productivity of Cardiovascular Investigators.

2019

Circulation

Taegtmeyer H, Dasgupta P

PubMed

Challenges for Today's Pediatric Physician-Scientists.

2018

JAMA pediatrics

Stoll BJ, Taegtmeyer H

PubMed

Temporal partitioning of adaptive responses of the murine heart to fasting.

2018

Life sciences

Brewer RA, Collins HE, Berry RD, Brahma MK, Tirado BA +10 more

Plain English
This study looked at how the timing of fasting affects the heart's health in mice. Researchers found that fasting during the night, when the mice are active, leads to beneficial changes in heart function, increasing certain proteins and decreasing glucose use. Conversely, fasting during the day boosted a process called autophagy, which helps cells recycle components. Who this helps: This helps patients with heart health issues and doctors looking for new strategies to improve cardiac function.

PubMed

Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

2018

Circulation

Taegtmeyer H, Karlstaedt A

PubMed

Sca-1cardiac fibroblasts promote development of heart failure.

2018

European journal of immunology

Chen G, Bracamonte-Baran W, Diny NL, Hou X, Talor MV +10 more

Plain English
This study focused on a specific type of heart cell called Sca-1 cardiac fibroblasts and their role in causing heart failure. The researchers found that these cells produce a substance called GM-CSF, which leads to inflammation and heart damage; in experiments, blocking a signaling pathway related to these cells led to fewer heart issues. This is important because it identifies a key player in heart failure, opening doors for new treatments to help protect the heart. Who this helps: Patients with heart failure and their doctors may benefit from these findings.

PubMed

Actionable Metabolic Pathways in Heart Failure and Cancer-Lessons From Cancer Cell Metabolism.

2018

Frontiers in cardiovascular medicine

Karlstaedt A, Schiffer W, Taegtmeyer H

Plain English
This study looked at how cancer cells change their metabolism and how this knowledge could help us understand and treat heart failure. The researchers found that the same processes that help cancer cells thrive may also be used to improve heart function. This matters because using these insights could lead to new treatments for people suffering from heart problems. Who this helps: Patients with heart failure.

PubMed

TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice.

2018

Cardiovascular therapeutics

Eblimit Z, Thevananther S, Karpen SJ, Taegtmeyer H, Moore DD +3 more

Plain English
This study looked at how a compound called cholic acid and its synthetic version (INT-777) affect heart function in mice. The researchers found that mice given these compounds had better exercise tolerance and fewer heart issues under stress, while mice lacking TGR5 (the protein these compounds activate) struggled and had higher mortality rates. This is important because it shows that activating TGR5 can help the heart handle stress better, which could lead to new treatments for heart failure. Who this helps: This helps patients with heart failure and their doctors.

PubMed

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

2018

European heart journal

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS +30 more

PubMed

Maternal-Fetal Parabiosis in Obesity Exposes Unexpected Roles for Cardiac Metabolism.

2018

JACC. Cardiovascular imaging

Taegtmeyer H

PubMed

Frequent Co-Authors

Anja Karlstaedt Philip L Lorenzi Lin Tan Efstratios Koutroumpakis Giovanni Davogustto Martin E Young Sara A Martinez Heidi Vitrac Vala Hamidi Hongyu Wang

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.